Praxis Precision Medicines Inc (NASDAQ:PRAX) — Market Cap & Net Worth
Market Cap & Net Worth: Praxis Precision Medicines Inc (PRAX)
Praxis Precision Medicines Inc (NASDAQ:PRAX) has a market capitalization of $8.72 Billion ($8.72 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2489 globally and #916 in its home market, demonstrating a -11.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Praxis Precision Medicines Inc's stock price $312.90 by its total outstanding shares 27878774 (27.88 Million). Also see Praxis Precision Medicines Inc total assets for a full breakdown of the balance sheet.
Praxis Precision Medicines Inc Market Cap History: 2020 to 2026
Praxis Precision Medicines Inc's market capitalization history from 2020 to 2026. Data shows change from $23.01 Billion to $8.72 Billion (-4.74% CAGR). Also see how efficiently does Praxis Precision Medicines Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Praxis Precision Medicines Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.33% | #57 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.02% | #289 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.46% | #39 of 263 |
Weight: Praxis Precision Medicines Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Praxis Precision Medicines Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Praxis Precision Medicines Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Praxis Precision Medicines Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
250.85x
Praxis Precision Medicines Inc's market cap is 250.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $995.27 Million | $1.46 Million | -$213.07 Million | 679.83x | N/A |
| 2023 | $621.14 Million | $2.45 Million | -$123.28 Million | 253.84x | N/A |
| 2024 | $2.15 Billion | $8.55 Million | -$182.82 Million | 250.85x | N/A |
Competitor Companies of PRAX by Market Capitalization
Companies near Praxis Precision Medicines Inc in the global market cap rankings as of September 16, 2026. Review PRAX intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Praxis Precision Medicines Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Praxis Precision Medicines Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Praxis Precision Medicines Inc's market cap moved from $23.01 Billion to $ 8.72 Billion, with a yearly change of -4.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.72 Billion | +6.16% |
| 2025 | $8.22 Billion | +282.98% |
| 2024 | $2.15 Billion | +245.42% |
| 2023 | $621.14 Million | -37.59% |
| 2022 | $995.27 Million | -87.92% |
| 2021 | $8.24 Billion | -64.19% |
| 2020 | $23.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Praxis Precision Medicines Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.72 Billion USD |
| MoneyControl | $8.72 Billion USD |
| MarketWatch | $8.72 Billion USD |
| marketcap.company | $8.72 Billion USD |
| Reuters | $8.72 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more